Merck's first full quarter post-merger demonstrates strong financial performance, exceeding expectations with growth in key products and successful integration progress. Management reaffirmed full-year and long-term targets, expressing confidence despite challenges like generic competition for COZAAR/HYZAAR and healthcare reform costs. The positive results and optimistic outlook are likely to positively influence the stock price in the short term.

[1]